Latest Cash Reserves News

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

Antipa Minerals has expanded gold-copper-lead-silver mineralisation at its Tim’s Dome target over more than a kilometre of strike, advancing diamond drilling to test a large untested electromagnetic conductor.

AVADA Group lifted revenue by nearly 15% in FY26, driven by Queensland and New South Wales expansion, while managing a $15 million impairment in Victoria that kept the statutory loss steady.

Liontown Limited (ASX:LTR) has reported its maiden profit and strong cash flow in FY26, completing its transition to fully underground mining at Kathleen Valley and advancing expansion plans with a final investment decision due early FY27.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.

Joyce Corporation Ltd (ASX: JYC) posted a record FY26 profit of $10.8 million, up 32% on normalised NPAT, underpinned by strong growth in its KWB kitchen and wardrobe business and improved Bedshed franchise performance. The company declared a fully franked final dividend of 17 cents, lifting the full-year payout to 30 cents per share.

Provaris Energy reported a $4.045 million loss for FY2026 as it progressed proprietary hydrogen and liquid CO₂ storage technologies, expanded strategic partnerships, and boosted cash reserves through multiple placements.

Orion Equities (ASX:OEQ) returned to profitability in FY26 with a $204,000 net profit, buoyed by a $400,000 uplift in investment property value. Despite a 7% dip in total revenue, net tangible asset backing per share edged up to $0.43, while no dividend was declared.

FlexiRoam Limited (ASX:FRX) reported a statutory net profit after tax of $0.7 million for FY26, reversing a $2.0 million loss in FY25, driven by a pivot to higher-quality recurring revenue and operational discipline.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.